

Supplementary information to accompany:
“GPS-estimated foot traffic data and venue selection for COVID-19
serosurveillance studies”

1 Supplemental Methods

1.1 Participant recruitment and study procedures

Spanish-, Portuguese-, and English-speaking study staff wearing personal protective equipment (PPE) contacted business patrons directly as they were leaving or entering the essential business location. This site was selected for its central location in the community, its status as an essential business not subject to state-mandated restrictions on in-person business activities, and the reliably high volume of people visiting the location each day. All adults over 18 years of age with no reported symptoms suggestive of active COVID-19 infection were eligible to participate in the study. Research staff reviewed study procedures (including post-study medical follow-up for patients with positive serology) and risks and benefits of study participation before offering potential participants the opportunity to provide verbal informed consent to participate. We recorded participants’ self-reported home locations (by ZIP code and electoral ward), how they learned about the study (to distinguish between participants directly recruited on-site and those who learned about the study from friends, family, or social media), and information on participants’ demographics, symptom history, household structure, and activities outside the home. We did not advertise or announce enrollment for the study prior to its implementation, with the goal of increasing the proportion of individuals recruited on site at the study location.

1.2 Serological testing

Participants underwent testing for SARS CoV-2-specific IgG and IgM using an immunochromatographic lateral flow assay (LFA, Biomedomics, Morrisville, North Carolina, USA). In prior validation studies using confirmed clinical cases of COVID-19 as known positives and pre-pandemic discarded blood samples as known negatives, the LFA was 90% sensitive among patients tested > 8 days after symptom onset and 99.2% specific [1]. Each LFA was interpreted by a board-certified pathologist and LFA results were provided to participants by a study physician. We considered a positive result for SARS-CoV-2 IgG, IgM, or both by LFA as evidence of prior infection. Results from point-of-care antibody testing were returned to patients by a physician on the study team.

1.3 Model-based comparison between variance reduction strategies for venue sampling

To understand how different sampling strategies impact variance of serology-based cumulative incidence estimates, we used a simple stochastic model that incorporates performance characteristics of serological testing and heterogeneity in cumulative incidence across location and age group. (Other demographic characteristics, including race and ethnicity, are not included in this example, but the model described here can be generalized to include any number of additional characteristics relevant for stratification.)

We assumed a simple synthetic population that is stratified over 6 age categories and 7 geographic units (corresponding to the seven electoral wards in Somerville), informed by age distribution and ward-level population data from Somerville. To specify the “true” cumulative incidence of infection by location and

age group, we assumed that the cumulative number of PCR-confirmed infections reported for each ward in Somerville, divided by the population of each ward, approximates the ward-level distribution of cumulative incidence across the city. We then assumed that the distribution of cumulative incidence across age groups matches observed distributions for reported cases in Massachusetts [2], and that the age distribution of cumulative incidence is the same for each ward. We used these assumptions to populate the matrix Θ , where each entry $\theta_{j,k}$ is the cumulative incidence of PCR-confirmed infection for age group j in ward k . In the subsequent analysis, we multiplied Θ by different values of m , to adjust for the factor by which true incident cases exceed detected cases, with m in $\{6, 7, 8, \dots, 40\}$ following estimates in [3] and [4]. We assumed that m is constant across locations and age groups (i.e. that case detection effort is equal across wards and age groups).

We next generated matrices describing different sampling strategies, \mathbf{S} , where each entry $n_{j,k}$ represents the number of serological test performed (equal to the number of study participants) in each location- and age-stratified population group and where n represents that total of all tests performed. We compare eight different sampling strategies:

S_U: uniform sampling of participants across age and location.

S_{LA}: non-uniform sampling, in which the number of participants tested in each age-population group is weighted by the distribution of the population by location and age group.

S_C: non-uniform sampling in which the number of participants tested in each age-population group is weighted by the observed geographic distribution of incident cases by ward in Somerville.

S_{CA}: non-uniform sampling, weighted by both the geographic distribution of incident cases and the population age distribution.

S_P: non-uniform sampling, weighted by the distribution of study participants directly recruited during venue sampling in our study.

S_{PA}: non-uniform sampling, weighted by the distribution of study participants recruited during venue sampling and by the population age distribution.

S_V: non-uniform sampling, weighted by the catchment distribution of GPS-estimated visitors to an alternate hypothetical study venue in East Somerville.

S_{VA}: non-uniform sampling, weighted by the catchment distribution of GPS-estimated visitors to an alternate hypothetical study venue in Somerville Ward 1, and the population age distribution

S_C corresponds to a serological testing strategy that, relative to uniform sampling, enriches for participants from areas with higher numbers of detected incident cases (individuals with RNA PCR-confirmed SARS-CoV2 infection) and relatively under-samples in locations with lower numbers of detected cases; **S_{CA}** is an extension of this strategy that also weights the sample by the age distribution in the population. **S_V** reflects a hypothetical sampling distribution that would be expected given the GPS-estimated catchment distribution for an alternate study located in an area with higher cumulative incidence of reported infections (Figure 1). In practice, **S_C** and **S_{CA}** could be replicated by choosing a venue sampling location with a predicted catchment distribution that closely matches the geographic distribution of incident cases (for example, a grocery store or other essential business located in an area with higher numbers of reported incident cases). Motivated by the observation that the highest incidence of reported cases are in Wards 1 and 4 of Somerville, we also examined **S_V** and **S_{VA}**, two sampling distributions based on the GPS-predicted catchment distribution of an alternative, hypothetical study venue (a different essential business location in East Somerville).

S_{LA} is an extension of “demographic-informed” sampling described by Larremore et al [5] that accounts for both demographic and geographic distribution of individuals in a given population. **S_P** and **S_{PA}** correspond to geographically unrestricted venue sampling, similar to the sampling strategy used in our study, in which the geographic distribution of study participants matches neither the geographic distribution of incident cases nor the geographic distribution of the local population.

The procedure for estimating variance for each sampling strategy is as follows: We first estimated the number of “true” prior infections in each age-location group, entries $i_{j,k}$ in matrix \mathbf{I} , by taking $n_{j,k}$ random

draws from a binomial distribution with probability $\theta_{j,k}$. The number of observed serological positives for each location-age group, entries $o_{j,k}$ of matrix \mathbf{O} , were subsequently drawn from a binomial distribution with probability equal to the serological test *sensitivity* and the number of false positives from a binomial distribution with probability equal to $1 - \textit{specificity}$. We estimated cumulative incidence using the total number of seropositives ($TP + FP$) for each age-location group ($o_{j,k}$) and estimated θ_w , the population-level cumulative incidence estimates weighted by the proportion of individuals in each age-location group. For each sampling strategy, we repeated this process 1000 times, over a range of plausible values for m (4-40) and n (350-1400), and estimated 95% confidence intervals from the resulting distribution of weighted-population level cumulative incidence estimates using the percentile method.

1.4 Multiple logistic regression for predictors of seropositivity

We report multiple logistic regression results from two different models: (1) a “full” model that included a pre-specified set of hypothesized predictors of seropositivity; (2) an “alternative model” identified using the stepwise algorithm for model specification in the R function *step*. We performed this analysis using data for all participants (Table S4) and for the subset of participants recruited directly at the study venue (Table S5). For the full model, we included gender, age, household size, language spoken at home, self-report prior symptoms (fever and cough), self-report of prior COVID-19 diagnosis (either self-diagnosis or diagnosis by a medical provider) or close contact with a confirmed COVID-19 case, and self-report of any risk activity (including work outside the home, public transit use, or visiting friends or family outside the home in the week prior). Participant home location was not included as a predictor, given the limited number of observations in each location category. We chose to include self-report of fever and cough, rather than other symptoms or an alternative combinations of symptoms, given that many of the other possible reported symptoms are non-specific for COVID-19. The alternative model, in which the model with the minimum possible AIC is identified via stepwise removal or addition of predictors, is reported for comparison. The same alternative model was identified in all cases, regardless of whether the stepwise algorithm is run in the forward or backward direction, and the same AIC-minimizing model was identified via exhaustive search over all possible combinations of predictors. Overall model performance was evaluated via likelihood ratio test (versus a null model with no predictors included) and the Hosmer-Lemeshow goodness-of-fit test.

1.5 Other statistical analysis

We calculated correlations between several ward-level metrics in Somerville (including *inter alia* cumulative incidence, study participants, and GPS-estimated home locations) using Pearson’s correlation coefficient r . We evaluated the significance of these correlations via permutation testing, wherein the observed value for r is compared against a null distribution of 10,000 r values obtained by randomly permuting ward assignments for the observed values for each variable. R code for this procedure is included at <https://github.com/svsero/COVID19serosurveillance-Somerville>.

2 Supplemental Figures & Tables




Figure S1: Geographic distributions of (A) self-reported reported home locations for directly-recruited participants (p_{direct}), (B) self-reported home locations all study participants (p_{all}), (C) GPS-estimated visitors to the study location (v_{site}), and (D) GPS-estimated visitors to an alternative, hypothetical study site in Somerville Ward 1 (v_{alt}). Insets show proportion of participants or visitors versus distance in kilometers from the study venue. Dark map areas and points designate wards contributing > 1% of the total participants or visitors for a given site, light blue designates wards contributing \leq 1%, and white are wards contributing zero participants or visitors.




Figure S2: Geographic distributions of (A) self-reported reported home locations for directly-recruited participants (p_{direct}), (B) self-reported home locations all study participants (p_{all}), (C) GPS-estimated visitors to the study location (v_{site}), and (D) GPS-estimated visitors to an alternative, hypothetical study site in Somerville Ward 1 (v_{alt}), restricted to wards contributing > 1% of total number of participants or visitors. The upper right panel includes a 10 km radius circle centered on the Somerville ward containing the study venue.




Figure S3: Comparison between observed catchment distribution of study participants (p_{all}) and observed incidence of SARS-COV2 PCR-confirmed infections reported to the Somerville Board of Health (θ_{PCR}). P values are estimated by comparing the observed r value versus a null distribution obtained by permutation of ward assignment for each variable (n=10,000 permutations)




Figure S4: Sampling strategy and uncertainty in SARS-CoV2 serosurveillance studies with geographic and demographic weighting. (A) Estimated weighted cumulative incidence $\hat{\theta}_w$ versus width of 95% confidence interval for different sampling strategies \mathbf{S}_{LA} , \mathbf{S}_{CA} , \mathbf{S}_{PA} , and \mathbf{S}_{VA} as described in the supplemental methods. Each point represents the results of 1000 simulations at given values for n (total number of tests) and m (multiplier by which the true underlying cumulative incidence exceeds reported, PCR-confirmed infections). (B) Relative uncertainty, as measured by the width of the 95% confidence interval for $\hat{\theta}_w$, compared between sampling strategies. Dashed line at intercept = 0 and slope = 1 demarcates where uncertainty for the two sampling strategies under consideration are equal to each other.




Figure S5: Relative uncertainty between demographic-weighted (x-axis: \mathbf{S}_{LA} , \mathbf{S}_{CA} , \mathbf{S}_{PA} , and \mathbf{S}_{VA}) and demographic-naïve (y-axis: \mathbf{S}_U , \mathbf{S}_C , \mathbf{S}_P , and \mathbf{S}_V). Each point represents the results of 1000 simulations at given values for n (total number of tests) and m and points are colored by the total number of tests n . Dashed line at intercept = 0 and slope = 1 demarcates where uncertainty for the two sampling strategies under consideration are equal to each other.

	All participants	Directly recruited	Somerville residents	Reference
Total	398	228	168	-
Recruitment				
Direct (on-site)	228 (0.57)	228 (1.0)	102 (0.61)	-
Word of mouth	133 (0.33)	0 (0.0)	52 (0.31)	-
Internet/social media	27 (0.07)	0 (0.0)	13 (0.08)	-
Other	10 (0.03)	0 (0.0)	1 (0.01)	-
Age				
18-19	9 (0.02)	1 (0.004)	3 (0.02)	(0.17)*
20-29	112 (0.28)	59 (0.26)	47 (0.28)	(0.26)
30-39	89 (0.22)	58 (0.25)	41 (0.24)	(0.23)
40-49	57 (0.14)	36 (0.16)	27 (0.16)	(0.12)
50-65	89 (0.22)	55 (0.24)	36 (0.21)	(0.13)
>65	42 (0.10)	19 (0.08)	14 (0.08)	(0.09)
Language				
English	321 (0.81)	169 (0.74)	137 (0.82)	(0.7)
Spanish	16 (0.04)	10 (0.04)	5 (0.03)	(0.07)
Portuguese	25 (0.06)	18 (0.08)	14 (0.08)	(0.06)
Other	36 (0.09)	31 (0.14)	12 (0.07)	(0.17)
Household size				
1	61 (0.15)	34 (0.15)	15 (0.09)	-
2	120 (0.30)	74 (0.32)	40 (0.24)	-
3	86 (0.22)	56 (0.25)	46 (0.27)	-
4	74 (0.19)	44 (0.19)	40 (0.24)	-
5	30 (0.08)	9 (0.04)	13 (0.08)	-
>5	27 (0.07)	11 (0.05)	14 (0.08)	-
Prior symptoms				
Any	201 (0.51)	104 (0.46)	86 (0.51)	-
Fever and cough	37 (0.09)	17 (0.07)	11 (0.065)	-
COVID-19 diagnosis				
Self-diagnosis	86 (0.22)	38 (0.17)	28 (0.17)	-
Provider, Confirmed	4 (0.01)	2 (0.009)	1 (0.006)	-
Provider, Suspected	11 (0.03)	3 (0.01)	4 (0.02)	-
COVID-19 contact				
Suspected	29 (0.07)	24 (0.11)	15 (0.09)	-
Diagnosed	41 (0.10)	10 (0.04)	14 (0.08)	-
Social distancing				
Work outside the home	120 (0.30)	77 (0.34)	41 (0.24)	-
Visit friends or family	148 (0.37)	89 (0.39)	62 (0.37)	-
Public transportation	45 (0.11)	30 (0.13)	23 (0.14)	-

Table S1: Demographic data, symptom history, self-reported COVID-19 diagnosis and exposure history, recruitment group, and exposure-associated activity history for study participants. Participants were asked if they had experienced any of the following 15 symptoms in the 12 weeks prior to the study: fever, chills, headache, muscle aches, fatigue, rhinorrhea, sore throat, chest pain, dyspnea, new loss of sense of smell or taste, nausea or vomiting, abdominal pain, diarrhea, and toe pain or discoloration. The Reference column lists 2015 demographic data for Somerville (population age structure and languages spoken at home [6]). *For the reference column, the youngest age category is 5-19 years old

	Tested	Seropositive	Cumulative Incidence		
			Unadjusted	Adjusted	95%CI
All participants	398	42	0.106	0.113	0.081,0.147
Somerville					
All Wards	168	11	0.065	0.071	0.035,0.113
Ward 1	4	0	0	-	-
Ward 2	63	5	0.079	0.095	0.035,0.170
Ward 3	42	3	0.071	0.095	0.025,0.188
Ward 4	9	1	0.111	0.202	0.031,0.450
Ward 5	17	1	0.059	0.110	0.013,0.250
Ward 6	24	0	0.000	-	-
Ward 7	5	0	0.000	-	-
Age					
0-19	9	2	0.222	0.302	0.086,0.576
20-29	112	9	0.080	0.089	0.043,0.146
30-39	89	6	0.067	0.077	0.029,0.136
40-49	57	5	0.088	0.107	0.039,0.183
50-65	89	14	0.157	0.181	0.110,0.261
>65	42	6	0.143	0.174	0.080,0.295
Language					
English	321	32	0.010	0.106	0.073,0.143
Spanish	16	6	0.375	0.440	0.231,0.658
Portuguese	25	1	0.040	0.078	0.009,0.192
Other	36	3	0.083	0.100	0.028,0.204
Household size					
1	61	8	0.131	0.155	0.083,0.247
2	120	9	0.075	0.084	0.040,0.142
3-5	190	23	0.121	0.134	0.089,0.186
>5	27	2	0.074	0.108	0.025,0.221
Prior symptoms					
None	197	19	0.096	0.105	0.065,0.151
Any	201	23	0.114	0.124	0.083,0.175
Fever and cough	37	5	0.135	0.148	0.059,0.264
COVID-19 diagnosis					
None	251	19	0.076	0.036	0.0122,0.0653
Self-diagnosis	86	17	0.198	0.228	0.150,0.315
Provider, confirmed	4	4	1	-	-
COVID-19 contact					
None	317	31	0.098	0.103	0.070,0.141
Confirmed	41	6	0.146	0.181	0.083,0.313
Social distancing					
No risk activity	145	13	0.090	0.099	0.055,0.147
Any risk activity	224	27	0.121	0.133	0.089,0.183

Table S2: Serology-based cumulative incidence estimates for all asymptomatic study participants with serological testing results, regardless of recruitment method, disaggregated by participant demographic information and self-reported history of COVID-19 related symptoms, prior COVID-19 diagnosis, case contact, and risk activities. Cumulative incidence estimates are adjusted for test performance following [5].

	Tested	Seropositive	Cumulative Incidence		
			Unadjusted	Adjusted	95%CI
Directly recruited participants	228	27	0.118	0.130	0.087,0.178
Somerville					
All Wards	102	10	0.098	0.111	0.057,0.174
Ward 1	4	0	0	-	-
Ward 2	43	5	0.116	0.140	0.059,0.236
Ward 3	27	3	0.111	0.152	0.046,0.279
Ward 4	4	0	0	-	-
Ward 5	11	1	0.091	0.170	0.029,0.379
Ward 6	9	0	0	-	-
Ward 7	1	0	0	-	-
Age					
0-19	1	0	0	-	-
20-29	59	6	0.102	0.122	0.054,0.207
30-39	58	6	0.103	0.124	0.052,0.212
40-49	36	2	0.056	0.081	0.015,0.183
50-65	55	10	0.182	0.216	0.119,0.336
>65	19	3	0.158	0.181	0.053,0.353
Language					
English	169	21	0.124	0.138	0.088,0.193
Spanish	10	3	0.3	0.384	0.145,0.681
Portuguese	18	0	0	-	-
Other	31	3	0.097	0.132	0.039,0.259
Household size					
1	34	7	0.206	0.243	0.119,0.388
2	74	5	0.068	0.080	0.026,0.144
3-5	109	15	0.138	0.155	0.090,0.230
>5	11	0	0	-	-
Prior symptoms					
None	124	13	0.105	0.117	0.0648,0.1756
Any	104	14	0.135	0.154	0.089,0.234
Fever and cough	17	2	0.118	0.173	0.041,0.353
COVID-19 diagnosis					
None	157	14	0.089	0.097	0.054,0.149
Self-diagnosis	38	9	0.237	0.281	0.155,0.428
Provider, confirmed	2	2	1	-	-
COVID-19 contact					
None	186	21	0.113	0.124	0.082,0.177
Confirmed	24	2	0.083	0.123	0.030,0.265
Social distancing					
No risk activity	79	12	0.152	0.174	0.0983,0.2605
Any risk activity	136	15	0.110	0.125	0.074,0.187

Table S3: Serology-based cumulative incidence estimates for participants recruited directly at the study site, disaggregated by participant demographic information and self-reported history of COVID-19 related symptoms, prior COVID-19 diagnosis, case contact, and risk activities. Cumulative incidence estimates are adjusted for test performance following [5].

Full model				
Predictor	β	SE β	p	e^β (95%CI)
Gender				
Male	-	-	-	
Female	-0.19	0.36	0.60	
Non-binary	-12.44	882.74	0.99	
Age				
18-30	-	-	-	
31-49	-0.30	0.50	0.55	
≥ 50	0.61	0.43	0.16	
Household size (persons)				
1	-	-	-	
2	-0.19	0.56	0.74	
≥ 3	-0.06	0.49	0.90	
Language				
English	-	-	-	
Spanish	1.48	0.65	0.02	4.39 (1.15,15.09)
Portuguese	-0.71	1.07	0.51	
Other	-0.03	0.67	0.96	
Prior symptoms				
Fever & cough	-0.32	0.60	0.60	
Prior diagnosis				
Provider, suspected or confirmed	0.74	0.66	0.26	
Self-diagnosis	1.23	0.40	0.00	3.4146 (1.53,7.51)
Case contact				
Confirmed	0.50	0.52	0.34	
Social distancing				
Any risk activity	0.43	0.37	0.25	
Model evaluation				
	χ^2	df	p	
Likelihood ratio test	30.16	15	0.01	
Hosmer & Lemeshow	10.64	6	0.10	
AIC: 256.90				
Alternative model				
Predictor	β	SE β	p	e^β (95%CI)
Age				
18-30	-	-	-	
31-49	-0.13	0.48	0.79	
≥ 50	0.79	0.41	0.05	2.20 (1.01,5.05)
Prior diagnosis				
Self-diagnosis	1.33	0.35	0.0001	3.78 (1.92,7.51)
Model evaluation				
	χ^2	df	p	
Likelihood ratio test	20.18	4	0.0002	
Hosmer & Lemeshow	0.01	3	0.99	
AIC: 244.89				

Table S4: Multiple logistic regression on predictors of seropositivity all study participants. The alternative model includes language spoken at home, provider diagnosis, and self-diagnosis as predictors. Self-diagnosis is identified as the single predictor significant at the 0.05 level in both the full and alternate models. Both the full and alternative models are significantly different from the null model via likelihood ratio test, and in both cases the Hosmer-Lemeshow test indicates that differences between observed and model-predicted seropositivity are not significant, rejecting the hypothesis of poor model fit.

Full model				
Predictor	β	SE β	p	e^β (95%CI)
Gender				
Male	-	-	-	
Female	-0.30	0.48	0.53	
Age				
18-30	-	-	-	
31-49	-0.32	0.62	0.60	
≥ 50	0.35	0.57	0.54	
Household size (persons)				
1	-	-	-	
2	-0.82	0.71	0.25	
≥ 3	-0.42	0.61	0.49	
Language				
English	-	-	-	
Spanish	0.95	0.92	0.30	
Portuguese	-16.80	1469.94	0.99	
Other	-0.40	0.73	0.59	
Prior symptoms				
Fever & cough	-0.47	0.93	0.61	
Prior diagnosis				
Provider, suspected or confirmed	2.02	1.30	0.12	
Self-diagnosis	1.28	0.54	0.02	3.61 (1.22,10.26)
Case contact				
Confirmed	-0.13	0.81	0.87	
Social distancing				
Any risk activity	-0.001	0.47	0.99	
Model evaluation				
	χ^2	df	p	
Likelihood ratio test	23.58	14	0.04	
Hosmer & Lemeshow	9.38	6	0.15	
AIC: 164.52				
Alternative model				
Predictor	β	SE β	p	e^β (95%CI)
Language				
English	-	-	-	
Spanish	0.90	0.86	0.29	
Portuguese	-17.28	1451.08	0.99	
Other	-0.45	0.71	0.52	
Prior diagnosis				
Provider, suspected or confirmed	2.37	1.23	0.05	
Self-diagnosis	1.16	0.49	0.018	3.20 (1.18,8.26)
Model evaluation				
	χ^2	df	p	
Likelihood ratio test	6	19.31	0.002	
Hosmer & Lemeshow	2	0.663	0.72	
AIC: 152.79				

Table S5: Multiple logistic regression on predictors of seropositivity among participants directly recruited at the study venue. The alternative model includes language spoken at home, provider diagnosis, and self-diagnosis as predictors. Self-diagnosis is identified as the single predictor significant at the 0.05 level in both the full and alternate models. Both the full and alternative models are significantly different from the null model via likelihood ratio test, and in both cases the Hosmer-Lemeshow test indicates that differences between observed and model-predicted seropositivity are not significant, rejecting the hypothesis of poor model fit.

References

- [1] V. Naranbhai, C. C. Chang, W. F. G. Beltran, T. E. Miller, M. G. Astudillo, J. A. Villalba, D. Yang, J. Gelfand, B. E. Bernstein, J. Feldman, B. M. Hauser, T. M. Caradonna, G. Alter, M. R. Murali, R. Jasrasaria, J. Quinlan, D. C. Xerras, J. R. Betancourt, D. N. Louis, A. G. Schmidt, J. Lennerz, M. C. Poznansky, and A. J. Iafate. High seroprevalence of anti-SARS-CoV-2 antibodies in Chelsea, Massachusetts. *J. Infect. Dis.*, Sep 2020.
- [2] Massachusetts State Department of Health. COVID-19 Response Reporting. <https://www.mass.gov/info-details/covid-19-response-reporting>.
- [3] Fiona P. Havers, Carrie Reed, Travis Lim, Joel M. Montgomery, John D. Klena, Aron J. Hall, Alicia M. Fry, Deborah L. Cannon, Cheng-Feng Chiang, Aridth Gibbons, and et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. *JAMA Internal Medicine*, Jul 2020.
- [4] S. L. Wu, A. N. Mertens, Y. S. Crider, A. Nguyen, N. N. Pokpongkiat, S. Djajadi, A. Seth, M. S. Hsiang, J. M. Colford, A. Reingold, B. F. Arnold, A. Hubbard, and J. Benjamin-Chung. Substantial underestimation of SARS-CoV-2 infection in the United States. *Nat Commun*, 11(1):4507, 09 2020.
- [5] Daniel B. Larremore, Bailey K. Fosdick, Kate M. Bubar, Sam Zhang, Stephen M. Kissler, C. Jessica E. Metcalf, Caroline Buckee, and Yonatan Grad. Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys. *medRxiv*, 2020.
- [6] City of Somerville, Massachusetts and Cambridge Health Alliance. The Wellbeing of Somerville Report. <https://www.somervillema.gov/>.